There are currently 341 ongoing clinical trials involving Metastatic Melanoma
Of the 341 trials,108 trials are in Phase II
Furthermore, 99 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Metastatic Melanoma, an Oncology condition. The largest number of ongoing clinical trials for Metastatic Melanoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Metastatic Melanoma-related drug trials.
University of Texas MD Anderson Cancer Center: The leading ongoing Metastatic Melanoma related clinical trial sponsor
University of Texas MD Anderson Cancer Center is the top sponsor for Metastatic Melanoma-related ongoing clinical trials.
National Cancer Institute US, Bristol-Myers Squibb Co, Novartis AG and H. Lee Moffitt Cancer Center & Research Institute Inc are among other notable clinical trial sponsors involved in Metastatic Melanoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Metastatic Melanoma
Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta) and Atezolizumab (Tecentriq) are among the key marketed drugs involving Metastatic Melanoma.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Pembrolizumab is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab was first approved in 2014 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Merck Sharp & Dohme Corp.
Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Nivolumab is formulated as a solution and concentrate solution for intravenous route of administration. Nivolumab was first approved in 2014 and is marketed globally in the US, UK, France, Germany and Japan by several prominent pharma giants including Bristol-Myers Squibb Co.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer